LUMENTRA
HEALTHCARE
SOLUTIONS
Delivering quality, affordable medicines to African markets — with 500+ formulations addressing the continent’s most pressing health challenges across Ghana and Kenya.
Company Overview
Lumentra Healthcare Solutions Pvt. Ltd. is an export-focused pharmaceutical company delivering quality, affordable medicines to African markets where healthcare demand is accelerating but supply remains fragmented. With over 500 formulations across 13 therapeutic categories, Lumentra is purpose-built to serve the continent’s dual burden of infectious diseases and rapidly rising chronic conditions.
Lumentra differentiates itself not through price alone, but through a complete partnership model: regulatory support, marketing collaboration, supply chain reliability, and a portfolio aligned precisely with the diseases driving the greatest burden in our target markets.
Export-Focused
Purpose-built pharma export model for Africa
Partnership Model
Beyond supply — full regulatory & marketing support
Africa-Centric
Products tailored for tropical climates & local needs
Quality Assured
GMP-compliant with Zone IVa/IVb stability data
Ghana & Kenya — Strategic Gateway Markets
Our primary focus markets represent a combined pharmaceutical opportunity exceeding $1.2 billion today and projected to surpass $1.8 billion before the end of this decade. Both countries serve as strategic regional gateways.
Ghana
West Africa Gateway
70% import-dependent. 34-35 local plants at below 55% capacity. Sources primarily from India & China. Strong opportunity for trusted generics supplier.
Kenya
East Africa Hub
Largest pharma market in East Africa. ~6% CAGR growth. Regional distribution & manufacturing hub. Heavy import reliance creates partnership opportunity.
Disease Burden & Portfolio Alignment
Both markets face a dual burden of infectious and chronic diseases. Lumentra’s portfolio maps directly to the leading causes of mortality and morbidity.
🇬🇭 Ghana — NCDs Rising
NCDs now cause more deaths than communicable diseases
🇰🇪 Kenya — Double Burden
Communicable diseases major but NCDs fast-rising
500+ Formulations Across 4 Strategic Pillars
🦠 Infectious Disease
124+ ProductsAntibiotics, artemether-lumefantrine antimalarials, antifungals for HIV co-infections, antiprotozoals, and anthelmintics. Aligned with WHO guidelines, government programs, and donor-funded initiatives across malaria-endemic and high-HIV-burden regions.
❤️ Chronic Disease
73+ ProductsAntihypertensives, statins, antiplatelets, oral antidiabetics, and lipid-lowering agents. Addresses the #1 adult killer in Ghana (stroke/CVD) and the fastest-growing mortality category in Kenya (CVD/diabetes).
💊 Primary Care
200+ ProductsAnalgesics/NSAIDs, PPIs, antacids, antispasmodics, antihistamines, cough/cold preparations, hematinics, and vitamin/mineral supplements. Supports Ghana’s push to improve community-level medicine availability.
🧬 Specialized
103+ ProductsPediatric formulations with child-friendly flavoring, women’s health, CNS therapies (epilepsy, anxiety, depression), and dermatological preparations. All with Zone IVa/IVb tropical stability data.
Product Efficacy & Treatment Outcomes
Antimalarial Clinical Response Rates
Artemether-Lumefantrine formulations demonstrate high efficacy in tropical conditions typical of Ghana and Kenya
Parasite Clearance
Fever Resolution
Hospital Stays
Cure Rate
Hypertension Management – Blood Pressure Control
Achievement of target blood pressure after 12 weeks of therapy with Lumentra antihypertensive medications
Stability Data in Zone IVa/IVb Conditions
Tropical climate stability testing confirms product efficacy in high temperature and humidity conditions
| Product Category | 30°C/75% RH 12 Months |
40°C/75% RH 6 Months |
Field Conditions Potency Retention |
|---|---|---|---|
| Antimalarials | 98.6% potency | 97.2% potency | Exceeds WHO requirements |
| Antibiotics | 99.1% potency | 97.8% potency | Excellent chemical stability |
| Cardiovascular | 99.3% potency | 98.7% potency | No significant degradation |
| Pediatric Syrups | 98.2% potency | 96.3% potency | Flavor/color stability maintained |
Problems Our Products Help Solve
🦟 Infectious Disease Burden
Antibiotics, antimalarials, antifungals and anthelmintics tackle pneumonia, UTIs, malaria, fungal and parasitic infections — reducing avoidable hospitalizations and mortality.
💓 Chronic Disease Epidemic
Cardiovascular and diabetes portfolios support long-term control of hypertension, heart disease, stroke risk and type 2 diabetes — the growing NCD crisis in African health systems.
🩹 Undertreated Pain
Extensive analgesic and NSAID options provide effective relief for acute and chronic pain, improving daily functioning and quality of life.
🫁 Respiratory & Allergic Conditions
Antihistamines and respiratory preparations offer symptomatic relief for allergic rhinitis, urticaria, and upper respiratory infections.
🩸 Micronutrient Deficiencies
Hematinics and supplements address iron-deficiency anemia and micronutrient gaps in children, women and vulnerable groups.
🧠 Mental Health & Skin Disease
CNS therapies manage epilepsy, anxiety and depression; dermatological topicals treat infectious and inflammatory skin conditions — reducing stigma and disability.
Supply Chain Capabilities
Robust logistics systems specifically designed for African markets
Export Infrastructure
Complete documentation management — CPP, Free Sale Certificates, WHO-type certificates. Experienced freight coordination for West & East African routes. Full Ghana FDA and Kenya PPB compliance. With 70% of Ghana’s medicines imported, reliability in documentation is a baseline — we treat it accordingly.
Climate-Adapted Integrity
All products stability-tested for Zone IVa/IVb tropical conditions. Extended shelf-life formulations for remote distribution. Packaging designed for multi-stage inland transport where cold-chain may be limited and ambient temps exceed 30°C.
Supply Continuity
Addressing the #1 supply chain pain point — stockouts. Buffer stock for essential medicines, demand forecasting based on epidemiological data, safety stock arrangements, and real-time order tracking for effective downstream planning.
Flexible Packaging
Bulk institutional packaging for tenders, standard retail configurations, and economical options for price-sensitive markets. Designed for both public procurement and out-of-pocket spending — the dominant payment mode.
Partnership Approach
Customized partnership models for Ghanaian and Kenyan stakeholders
🤝 Distribution Agreements
Strategic alliances with established distributors. Territory-specific arrangements, competitive pricing for tender-driven and retail environments, and performance-based incentives. Structured to reward consistency and growth — buyers increasingly prioritize reliable partners over the cheapest option.
📑 Regulatory & Market Access Support
Complete dossier preparation for Ghana FDA & Kenya PPB. Regulatory liaison throughout approval lifecycle, post-registration maintenance, variation submissions, and renewal management. Labeling proposals and tropical stability data coordination.
💰 Commercial Flexibility
Extended payment terms, volume-tiered pricing, consignment stock for launches. Market development funds for joint promotions, exhibitions, and government tender participation.
🎓 Healthcare Professional Engagement
Product training for sales teams, CME programs for prescribers, co-developed promotional materials adapted to local treatment guidelines. Building healthcare professional trust as the most valuable commercial asset.
🏭 Technology Transfer
Ghana’s 34-35 plants at below 55% capacity = unique opportunity. Contract manufacturing collaborations, local packaging operations, and knowledge transfer aligned with national policy to strengthen domestic production. Similar opportunities in Kenya’s regional hub.
Meaningful Local Operations
Establishing permanent, embedded presence in both markets
Local Representation
In-country offices with regulatory specialists experienced in Ghana FDA and Kenya PPB processes, medical affairs professionals for clinical engagement, and commercial managers who understand local distribution dynamics and tender cycles. Permanent coordination points — not temporary project teams.
Phased Registration
Strategic phased approach prioritizing Essential Medicines List alignment, highest-burden diseases, and documented supply gaps. Wave 1: antimalarials, antibiotics, cardiovascular, antidiabetic. Subsequent phases expand based on market feedback and timelines.
Community Investment
Public health campaign participation, essential medicine access in underserved areas, NGO and donor program collaboration, university partnerships and pharmacy school training initiatives. Responsibility as a foundation for sustainable growth.
Growth Roadmap
From initial distributor partnerships → direct institutional supply → regional warehousing → potential local manufacturing investment. Goal: become an embedded, indispensable partner in the healthcare delivery systems of both Ghana and Kenya.
Why Partner With Lumentra?
Extensive Portfolio
500+ products addressing diverse therapeutic needs across 13 categories
Market-Aligned
Products mapped to documented disease burdens in Ghana & Kenya
Quality Assured
GMP-compliant, Zone IVa/IVb stability, full regulatory documentation
True Partnership
Regulatory, marketing, training, and supply chain support included
Competitive Pricing
Affordable generics with flexible commercial terms for mutual profitability
Growth Oriented
Long-term investment vision from distribution to local manufacturing
Contact Information
We look forward to building successful partnerships that improve healthcare access across Africa.